Glucagon Archives - PharmaLive

Eli Lilly deals another blow to diabetes with latest FDA approval

Approvals, Chronic Diseases, Diabetes, Diabetes, Diabetes, Diabetes drugs, Eli Lilly, FDA, Glucagon, Glucagon-Like Peptide-1 (GLP-1) Analogs, Peptide Hormones, Therapeutics, Type 2 Diabetes

Eli Lilly scored another win against diabetes as the company’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide won approval under Priority Review from the U.S. Food and Drug Administration.

May 16, 2022/by BioSpace

Boehringer Ingelheim Launches Weight-Loss Trials for NASH

Antibiotic resistance, Boehringer Ingelheim, Business, Clinical Trials, Glucagon, Glucagon-Like Peptide-1 (GLP-1) Analogs, Infusions, Lyme Disease, Non-alcoholic steatohepatitis (NASH), Obesity, Overweight, Partnerships, R&D

Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

April 15, 2021/by Andrew Humphreys

FDA approves Xeris’ glucagon pen for low blood sugar

Approvals, Blood Sugar Levels, Diabetes, Fatty Acids, FDA, FDA/Regulatory, Glucagon, Hypoglycemia, Insulin, Pancreas, Pre-Filled Pens

The U.S. Food and Drug Administration approved Xeris Pharmaceuticals Inc.’s glucagon pen Gvoke, which aims to treat severely low sugar levels in diabetes patients.

September 10, 2019/by Reuters Health

FDA Approves First Needle-Free Glucagon to Treat Severe Hypoglycemia

Approvals, FDA, FDA/Regulatory, Glucagon, Medical Devices, Nasal drug delivery, Needle-Free, Peptide Hormones, Severe Hypoglycemia, Type 1 Diabetes, Type 2 Diabetes

The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.

July 25, 2019/by BioSpace